These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25166023)

  • 81. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
    Jeong SI; Ban MS; Hwang JG; Park MK; Lim S; Kim S; Kwon SK; Kim Y; Cho JM; Na JJ; Huh W; Chung JY
    Diabetes Obes Metab; 2024 Jul; 26(7):2588-2597. PubMed ID: 38618974
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 83. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
    Scheen AJ
    Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
    Kadokura T; Akiyama N; Kashiwagi A; Utsuno A; Kazuta K; Yoshida S; Nagase I; Smulders R; Kageyama S
    Diabetes Res Clin Pract; 2014 Oct; 106(1):50-6. PubMed ID: 25149596
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
    Tosaki T; Kamiya H; Himeno T; Kato Y; Kondo M; Toyota K; Nishida T; Shiroma M; Tsubonaka K; Asai H; Moribe M; Nakaya Y; Nakamura J
    Intern Med; 2017; 56(6):597-604. PubMed ID: 28321056
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
    Polidori D; Sha S; Mudaliar S; Ciaraldi TP; Ghosh A; Vaccaro N; Farrell K; Rothenberg P; Henry RR
    Diabetes Care; 2013 Aug; 36(8):2154-61. PubMed ID: 23412078
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
    Taylor SI; Cherng HR; Shahidzadeh Yazdi Z; Montasser ME; Whitlatch HB; Mitchell BD; Shuldiner AR; Streeten EA; Beitelshees AL
    Diabetes Obes Metab; 2023 Dec; 25(12):3512-3520. PubMed ID: 37608471
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.
    Davidson JA; Aguilar R; Lavalle González FJ; Trujillo A; Alba M; Vijapurkar U; Meininger G
    Ethn Dis; 2016 Apr; 26(2):221-8. PubMed ID: 27103773
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
    John M; Cerdas S; Violante R; Deerochanawong C; Hassanein M; Slee A; Canovatchel W; Hamilton G
    Int J Clin Pract; 2016 Sep; 70(9):775-85. PubMed ID: 27600862
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
    Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
    Devineni D; Polidori D; Curtin C; Stieltjes H; Tian H; Wajs E
    Clin Ther; 2016 Jan; 38(1):89-98.e1. PubMed ID: 26687552
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
    Inagaki N; Kondo K; Yoshinari T; Ishii M; Sakai M; Kuki H; Furihata K
    Clin Drug Investig; 2014 Oct; 34(10):731-42. PubMed ID: 25200141
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    Curr Med Res Opin; 2015 Jan; 31(1):137-43. PubMed ID: 25356602
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
    Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
    Bilezikian JP; Watts NB; Usiskin K; Polidori D; Fung A; Sullivan D; Rosenthal N
    J Clin Endocrinol Metab; 2016 Jan; 101(1):44-51. PubMed ID: 26580234
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.
    Osonoi T; Gouda M; Kubo M; Arakawa K; Hashimoto T; Abe M
    Diabetes Technol Ther; 2018 Oct; 20(10):681-688. PubMed ID: 30096243
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.
    Qiu R; Capuano G; Meininger G
    J Clin Transl Endocrinol; 2014 Jun; 1(2):54-60. PubMed ID: 29159083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.